{"eventGroups":[{"deathsNumAffected":16,"deathsNumAtRisk":20,"description":"Galinpepimut-S + Montanide + GM-CSF","id":"EG000","otherNumAffected":17,"otherNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"title":"Galinpepimut-S"},{"deathsNumAffected":20,"deathsNumAtRisk":21,"description":"Montanide + GM-CSF","id":"EG001","otherNumAffected":10,"otherNumAtRisk":21,"seriousNumAffected":1,"seriousNumAtRisk":21,"title":"Control"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Surgical and medical procedures","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":20,"numEvents":17},{"groupId":"EG001","numAffected":9,"numAtRisk":21,"numEvents":9}],"term":"Injection site reaction"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":20,"numEvents":10},{"groupId":"EG001","numAffected":10,"numAtRisk":21,"numEvents":10}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":20,"numEvents":0},{"groupId":"EG001","numAffected":4,"numAtRisk":21,"numEvents":4}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":20,"numEvents":0},{"groupId":"EG001","numAffected":2,"numAtRisk":21,"numEvents":2}],"term":"Arthralgias"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":20,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":21,"numEvents":0}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":21,"numEvents":1}],"term":"Rash, maculopapular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":21,"numEvents":1}],"term":"Lymphopenia"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":20,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":21,"numEvents":1}],"term":"Lymphopenia"}],"timeFrame":"Up to 5 years and 11 months, from either start of study or randomization, until primary completion (Nov 2016)"}